EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Durable Response to Redifferentiation in a Patient With Metastatic NCOA4::RET Fusion-driven Papillary Thyroid Cancer

Valentina D Tarasova iD, Christine H Chung, Sarimar Agosto Salgado

JCEM Case Reports · 18.04.2025 · 3 (6)

DOI: 10.1210/jcemcr/luaf054 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JCEM Case Reports, online erschienen am 05.05.2025. Verfasst von Valentina D Tarasova und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Redifferentiation therapy (RDT) is a promising strategy for follicular cell-derived thyroid cancer (TC) in the era of personalized oncology. Limited data are available on long-term clinical outcomes of RDT in patients with fusion-driven TC. A 22-year-old female with recurrent radioactive iodine (RAI)-refractory metastatic progressive, NCOA4::RET fusion-driven papillary TC was treated with selective RET inhibitor, selpercatinib, for 3 months before a therapeutic dose of RAI 146 mCi (5402 MBq). The posttherapy scan showed enhancement of RAI avidity of previously mildly avid pulmonary metastases. After RDT, the thyroglobulin levels significantly declined, and pulmonary nodules completely resolved on chest computed tomography scan. At 24 months of follow-up, the patient did not have evidence of progression. Moreover, thyroglobulin levels continued to decline. RDT with selpercatinib enhanced RAI uptake in the lungs, with a persistent structural and biochemical response sustained 24 months after RAI therapy and discontinuation of selpercatinib. Clinical trials are warranted further to investigate RDT with selective inhibitors in oncogene fusion-driven TC.

Schlagwörter

Stichwörter der Autor:innen

RAI-refractory thyroid cancerRET fusionredifferentiationselpercatinib

Autor:innen und Institutionen

  • Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA.

ORCID-Profile: Valentina D Tarasova

Zitieren

APA

Tarasova, V. D., Chung, C. H., & Agosto Salgado, S. (2025). Durable Response to Redifferentiation in a Patient With Metastatic NCOA4::RET Fusion-driven Papillary Thyroid Cancer. JCEM Case Reports, 3(6). https://doi.org/10.1210/jcemcr/luaf054

Vancouver

Tarasova VD, Chung CH, Agosto Salgado S. Durable Response to Redifferentiation in a Patient With Metastatic NCOA4::RET Fusion-driven Papillary Thyroid Cancer. JCEM Case Reports. 2025;3(6). doi:10.1210/jcemcr/luaf054

BibTeX
@article{Tarasova2025,
  author = {Tarasova, Valentina D and Chung, Christine H and Agosto Salgado, Sarimar},
  title = {Durable Response to Redifferentiation in a Patient With Metastatic NCOA4::RET Fusion-driven Papillary Thyroid Cancer},
  journal = {JCEM Case Reports},
  year = {2025},
  volume = {3},
  number = {6},
  doi = {10.1210/jcemcr/luaf054}
}
Kostenlos starten →